A mere 14% of pharma think they have sufficient medication adherence data for all products in their portfolio says S3 Survey.
This article in reuters highlight the strong need for solution that can provide accurate insights into the medical adherence of patients. Click here for full article.
Below is an excerpt of the the article. The problem mentioned here makes a very strong case for a solution like PillsMinder. :
This data is elusive because of the regulatory constraints on pharma, which make it difficult for them to interact with patients and gather data outside of a clinical trial setting. This real world data is becoming more important for pharma companies, with 82% of respondents indicating that pharma payers and regulators are putting them under increasing pressure to provide real world data. Click here for full article.